Died 28th April, 1977.
1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
THE TREATMENT OF UTERINE BLEEDING WITH VASOPRESSIN HORMONOGEN (GLYPRESS1N)—A PILOT STUDY
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1978.tb15832.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 85, Issue 11, pages 801–805, November 1978
Additional Information
How to Cite
Pavlin, V., Flynn, M. J., Mulder, J. L. and Cort, J. H. (1978), THE TREATMENT OF UTERINE BLEEDING WITH VASOPRESSIN HORMONOGEN (GLYPRESS1N)—A PILOT STUDY. BJOG: An International Journal of Obstetrics & Gynaecology, 85: 801–805. doi: 10.1111/j.1471-0528.1978.tb15832.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Abstract
- References
- Cited By
Summary
In a pilot study 12 women with severe uterine bleeding received an intravenous injection of 0 - 2 mg of a vasopressin hormonogen, glypressin. In 11 of the patients a rapid reduction or cessation of blood loss were observed. Two patients had facial pallor following the injection but no other side effects occurred. Five of the older women with long histories of menorrhagia were placed on a regime of one injection of glypressin on the first day of menstruation for six months; in all of them the duration of bleeding was reduced to three days and the monthly blood loss became very slight. On the basis of these results more extensive clinical trials in menorrhagia and metrorrhagia are recommended.